Why the study?
AQP4+NMOSD and MOGAD are rare conditions with evolving diagnostic and therapeutic approaches that needed to be described in France.
Cohort
Yes
p-value: p=< 0.001
This nationwide French registry demonstrates a reduction in time to diagnosis, decreased disease activity, and a lower risk of reaching EDSS 3 or 6 in MOGAD compared to AQP4+NMOSD over the past 15 years.
OBJECTIVES: Aquaporin 4-immunoglobulin G-seropositive neuromyelitis optica spectrum disorder (AQP4+NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are rare conditions with evolving diagnostic and therapeutic approaches. Our study aims to describe these evolutions in France, using data from the NOMADMUS cohort. METHODS: We retrospectively analyzed clinical, imaging, and therapeutic data collected across 98 French centers as of June 8, 2024. Patients were classified based on serologic status into AQP4+NMOSD or MOGAD. RESULTS: < 0.001, 0.21-0.68). Risk to reach EDSS 3 or 6 was lower in patients with MOGAD compared with AQP4+NMOSD patients. DISCUSSION: This nationwide registry revealed a reduction of the time to diagnosis, a decreased disease activity over time, and an evolution in the therapeutic strategies these past 15 years. This collaborative effort provides valuable insights into current knowledge about clinical practice and treatment patterns in real-world settings.
No takes yet. Share an insight, caveat, or question.
Roux et al. (2026) conducted a cohort in Aquaporin 4-immunoglobulin G-seropositive neuromyelitis optica spectrum disorder (AQP4+NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). MOGAD vs. AQP4+NMOSD was evaluated on Risk to reach EDSS 3 or 6 (95% CI 0.21-0.68, p=< 0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: